The biotechnology R&D intensity in the US business sector is forecasted to show a steady increase from 2024 to 2028, starting at 18.21% of BERD in 2024 and rising to 18.93% in 2028. This consistent growth, albeit modest, indicates a positive trend towards increasing investment in biotechnology research and development within the sector.
The year-on-year variation in percentage demonstrates a gradual increase with future values indicating a continued upward trajectory. For instance, from 2024 to 2025, there is a rise from 18.21% to 18.46%, followed by further increments in subsequent years. The compound annual growth rate (CAGR) over this forecast period reflects an average annual growth rate, showcasing the sector's commitment to enhancing R&D intensity.
Future trends to watch for include potential impacts of regulatory changes, shifts in funding priorities, advancements in biotechnology that may spur further investment, and the overall economic climate influencing R&D expenditures. Keeping an eye on these factors will be essential for understanding the long-term trajectory of biotechnology R&D intensity in the business sector.
